Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 10;386(6):599-601.
doi: 10.1056/NEJMc2119641. Epub 2021 Dec 30.

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Fabian Schmidt  1 , Frauke Muecksch  1 , Yiska Weisblum  1 , Justin Da Silva  1 , Eva Bednarski  1 , Alice Cho  1 , Zijun Wang  1 , Christian Gaebler  1 , Marina Caskey  1 , Michel C Nussenzweig  1 , Theodora Hatziioannou  1 , Paul D Bieniasz  1
Affiliations

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Fabian Schmidt et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Wuhan-hu-1, PMS20, and Omicron Plasma Neutralizing Titers.
Panel A shows the trajectories of NT50 values against Wuhan-hu-1, polymutant spike protein (PMS20), and omicron pseudotypes in previously unvaccinated persons who had recovered from Covid-19, measured approximately 1 month (mean ±SD, 41±12 days) and 6 months (194±12 days) after infection and then at approximately 1 year (360±15 days) after infection, which corresponded to 41±21 days after vaccination (“plus vaccine”) (see Table S2). Panel B shows the trajectories of NT50 values against Wuhan-hu-1, PMS20, and omicron pseudotypes in persons who had received an mRNA vaccine, measured 1 month (42±19 days) and 5 months (165±33 days) after the second dose of an mRNA vaccine and at 30±18 days after the third dose (“boost”) that was administered at least 6 months after the second dose.
See this image and copyright information in PMC

Update of

References

    1. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398:2126-2128. - PMC - PubMed
    1. Schmidt F, Weisblum Y, Rutkowska M, et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 2021;600:512-516. - PMC - PubMed
    1. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020;584:437-442. - PMC - PubMed
    1. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591:639-644. - PMC - PubMed
    1. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021;595:426-431. - PMC - PubMed

Publication types

Supplementary concepts